Alpha Tau Medical Ltd.
Close on Oct 19, 2026
- Market cap
- –
- P/E (TTM)
- –
- Dividend yield
- –
About Alpha Tau Medical
Surgical & Medical Instruments & Apparatus, SIC 3841
Alpha Tau Medical Ltd. is a clinical-stage medical device oncology therapeutics company focused on the development of its proprietary Alpha DaRT technology. The technology is designed to treat solid tumors through alpha irradiation via the intratumoral insertion of radium-224 impregnated sources, providing localized radiotherapy. The company evaluates its treatment across multiple cancer types, including skin, oral, pancreatic, prostate, lung, liver, and brain cancers. Alpha Tau Medical does not currently market products commercially or generate revenue, and its activities center on clinical, scientific, and preclinical programs for cancer patients.
The company operates its corporate headquarters and principal executive offices in Jerusalem, Israel. Its clinical trials and preclinical research take place in the United States and various international jurisdictions, with marketing authorizations held in Israel and Japan. Alpha Tau Medical also maintains operational activities and facilities to establish manufacturing infrastructure capable of producing its Alpha DaRT technology.
Summary of the business section of Alpha Tau Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Alpha Tau Medical Ltd.
- Founded
- 2016
- Headquarters
- Jerusalem, L3
- Address
- Kiryat Hamada 5 9777605
- Phone
- 972-3-577-4115
- Website
- alphatau.com
- Employees
- 130, Dec 31, 2025
- Industry
- Surgical & Medical Instruments & Apparatus
- Incorporated in
- L3
- Fiscal year ends
- December 31
- Auditor
- KOST FORER GABBAY & KASIERER, Tel-Aviv, Israel
Stock & identifiers
- Ticker
- DRTS
- Other tickers
- DRTSW
- Exchange
- Nasdaq
- IPO date
- Mar 8, 2021
- Shares outstanding
- 88M, Dec 31, 2025
- Filer category
- Accelerated filer<br>Emerging growth company
- SEC CIK
- 1871321
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Uzi Sofer | Chief Executive Officer, Director | 4,680 |
| Raphi Levy | Chief Financial Officer | 93,051 |
| Maya Netser | Director | 4,680 |
| Michael Avruch | Director | 1,571,961 |
| David Mark Milch | Director | 118,110 |
| Alan Adler | Director | 54,367 |
| Nadav Kidron | Director | 2,986 |
| S. Morry Blumenfeld | Director | 4,680 |
| Ruth Alon | Director | 4,680 |
Employees
Headcount reported in annual reports
“Of our total 130 employees as of December”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 7, 2022 | Listing | Registration of securities on an exchange (Form 8-A) |
| Aug 19, 2021 | Merger | Registration of securities for a merger or exchange offer (S-4) |